Oryzon Genomics SA Company Profile, Contacts & Intelligence

BiotechnologyCornella De Llobregat, Barcelona, Es58 employeesFounded 2000
4 contacts with email or phone data4 with email data1 with phone data
View verified contacts Compare competitors
Employees
58
Company source estimate
Reachable Contacts
4
Visible contacts with email or phone data
Contacts With Email
4
4 of 4 visible contacts
Departments
3
Mapped contact coverage

Oryzon Genomics SA Overview

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in 2000 and has offices in Spain and the United States.

Headquarters
Cornella De Llobregat, Barcelona, Es
Website
oryzon.com
Industry
Biotechnology
Founded
2000
Phone Number
Available in AeroLeads
Company Email
Available in AeroLeads
Drug discovery and development biomarker discovery cancer neurodegeneration epigenetics clinical trials

Oryzon Genomics SA Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

4 contacts with contact data
4 with email data and 1 with phone data in the visible sample.
3 departments represented
Visible contacts with email or phone data are mapped to these departments.
3 company-domain emails
Visible contacts using Oryzon Genomics SA's company email domain.
IT
2
General
2
Executive
1

Oryzon Genomics SA People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

E
Emili Torrell
Director Business Development & Licensing at Oryzon Genomics Sa
EP
C
Carlos Buesa
E
T
Tamara Maes
Founder, Oryzon Genomics Sa
E
M
Michael T Ropacki
Chief Medical Officer, Cns Clinical Development at Oryzon Genomics Sa
E

Oryzon Genomics SA Workforce Composition

Seniority breakdown across 11 visible profiles.

Individual contributor
4
Manager
3
Executive
2
VP / Head
1
Director
1

Oryzon Genomics SA Technology & Talent

Technology-related job titles represented in the visible people data.

Data / AI
2

Compare Similar Companies to Oryzon Genomics SA

Explore companies in related markets and compare their industry and employee estimates.

Company Industry / match Employee estimate Page
Almirall Pharmaceutical Manufacturing 2.33K View company
Sequentia Biotech Biotechnology 49 View company
SpliceBio Biotechnology 47 View company
ONA Therapeutics Biotechnology Research 36 View company
Minoryx Therapeutics Biotechnology 33 View company
Nuage Therapeutics Biotechnology Research 25 View company
Flomics Biotechnology Research 24 View company
Peptomyc Research Services 21 View company
OneChain Immunotherapeutics Biotechnology Research 19 View company
AELIX Therapeutics Biotechnology Research Not listed View company